Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 31, Issue 2, pp 233–234 | Cite as

A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty

  • M. Silvano
  • C. F. Zambon
  • G. De Rosa
  • M. Plebani
  • V. Pengo
  • M. Napodano
  • R. PadriniEmail author
Article

Dual antiplatelet therapy (aspirin and clopidogrel) is the standard therapy to prevent stent thrombosis after percutaneous coronary angioplasty. Clopidogrel is a prodrug which requires two-step activation through oxidative metabolism, involving various cytochrome P-450 (CYP) enzymes [1]. Carriers of defective alleles for CYP2C19 (*2) and CYP2C9 (*2, *3) have a reduced antiplatelet effect in response to clopidogrel [2, 3]. In addition, CYP3A4 in vivo activity measured by the erythromycin breath test is significantly correlated with the ability of clopidogrel to inhibit platelet aggregation [4]. Lastly, it has been reported that omeprazole and atorvastatin—which are inhibitors of CYP2C19 and CYP3A4, respectively—can reduce the effect of clopidogrel in man [5, 6]. Thus, there is clinical evidence that the activity of at least three cytochromes determines the effectiveness of clopidogrel in vivo.

We report a case of early stent thrombosis associated with clopidogrel resistance in a...

Keywords

Clopidogrel Omeprazole Stent Thrombosis P2Y12 Receptor Prasugrel 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ellis KJ, Stouffer GA, McLeod HL, Lee CR (2009) Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics 10:1799–1817CrossRefPubMedGoogle Scholar
  2. 2.
    Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354–362CrossRefPubMedGoogle Scholar
  3. 3.
    Harmsze A, van Werkum JW, Bouman HJ, Ruven HJ, Breet NJ, Ten Berg JM, Hackeng CM, Tjoeng MM, Klungel OH, de Boer A, Deneer VH (2010) Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics 20:18–25CrossRefPubMedGoogle Scholar
  4. 4.
    Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bates ER (2004) Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109:166–171CrossRefPubMedGoogle Scholar
  5. 5.
    Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301:937–944CrossRefPubMedGoogle Scholar
  6. 6.
    Clarke TA, Waskell LA (2003) The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 31:53–59CrossRefPubMedGoogle Scholar
  7. 7.
    Gori AM, Marcucci R, Paniccia R, Giusti B, Fedi S, Antonucci E, Buonamici P, Antoniucci D, Gensini GF, Abbate R (2008) Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function. Thromb Haemost 100:1136–1145PubMedGoogle Scholar
  8. 8.
    Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, Woosley RL, Flockhart DA (1995) The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 57:662–669CrossRefPubMedGoogle Scholar
  9. 9.
    Böttiger Y (2006) Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4. Eur J Clin Pharmacol 62:621–625CrossRefPubMedGoogle Scholar
  10. 10.
    Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias WL, Braunwald E, Sabatine MS (2009) Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119:2553–2560CrossRefPubMedGoogle Scholar
  11. 11.
    Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P (2003) Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108:989–995CrossRefPubMedGoogle Scholar
  12. 12.
    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Cavallari U, Trabetti E, Sabaté M, Jimenez-Quevedo P, Hernández R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Costa MA, Bass TA, Pignatti PF, Macaya C (2005) Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 116:491–497CrossRefPubMedGoogle Scholar
  13. 13.
    Eshtehardi P, Eslami M, Moayed DA (2008) Simultaneous subacute coronary drug-eluting stent thrombosis in two different vessels of a patient with factor V Leiden mutation. J Cardiovasc Med 9:410–413CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • M. Silvano
    • 1
  • C. F. Zambon
    • 2
  • G. De Rosa
    • 3
  • M. Plebani
    • 2
  • V. Pengo
    • 1
  • M. Napodano
    • 1
  • R. Padrini
    • 3
    Email author
  1. 1.Department of Cardiothoracic and Vascular SciencesUniversity of PadovaPadovaItaly
  2. 2.Department of Laboratory MedicineUniversity of PadovaPadovaItaly
  3. 3.Department of Clinical and Experimental MedicineUniversity of PadovaPadovaItaly

Personalised recommendations